Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MCAR -- Ignore unavailable to you. Want to Upgrade?

To: richroni who wrote (158)	3/27/1998 5:54:00 PM
From: Andrew Q. Viet	Read Replies (1) \| Respond to of 467

since MCAR trades on the bulletin board, it needs to report once every 6 months. However, they are in the process of waiting for Nasdaq listing approval. Their treatment systems are proprietary, but not patentable, so in theory anyone can duplicate their technologies. But the market is big enough for everyone and it would take a few years for other players to establish their treatment networks. I think once MCAR has the name recognition among urologists, it's very difficult for new players to enter the market. MCAR positions itself in a clever way by establishing their treatment systems inside doctor's offices. It gives doctors additional incentive to recruit patients, for both MCAR and doctors can benefit from this. It costs MCAR from $18-22,000 to open each site, so I believe within 2 years MCAR will become entrenched and new players will have a tough time to compete with MCAR in the same market. MCAR is establishing a connection with most well-known urologists in the country and this will bolster MCAR name recognition. OFF topic: About the news from PNU:I meant MCAR price impact, not business impact.

To: richroni who wrote (158)	3/29/1998 12:30:00 AM
From: Andrew Q. Viet	Read Replies (1) \| Respond to of 467

Taken from their latest 10K 4.8 INTELLECTUAL PROPERTY. The Company has valid, unrestricted and exclusive patents, trademarks, trademark registrations, trade names, copyrights,know-how, technology and other intellectual property necessary to the conduct of its business as set forth on Exhibit L-l. The Company has granted such licenses or has assigned or otherwise transferred a portion of (or all of) such valid, unrestricted and exclusive patents, trademarks, trademark registrations, trade names, copyrights, know-how, technology and other intellectual property necessary to the conduct of its business as set forth on Exhibit L-2. The Company has been granted licenses, know-how, technology and/or other intellectual property necessary to the conduct of its business as set forth on Exhibit L-3. To the best of the Company's knowledge, the Company is not infringing on the intellectual property rights of any third party, nor is any third party infringing on the Company's intellectual property rights. There are no restrictions in any agreements, licenses, franchises, or other instruments which preclude the Company from engaging in its business as presently conducted.